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Natalizumab (Tysabri®) is a monoclonal antibody that prevents inflammatory cells from
binding to brain endothelial cells and passing into the brain parenchyma. Natalizumab
is a highly effective treatment for relapsing-remitting multiple sclerosis (MS). Progres-
sive multifocal leukoencephalopathy (PML) is an opportunistic brain JC virus infection
that has been shown to be associated with natalizumab treatment. We describe PML
in a patient with MS after 44 monthly infusions of natalizumab. With the aid of a routine
Magnetic resonance imaging (MRI) scan, PML was detected before any unambiguous clin-
ical manifestations had emerged. PML was treated with plasma exchange to accelerate
removal of natalizumab. Mirtazapine and mefloquine was promptly added and approxi-
mately 1 month after plasma exchange, when an immune-reconstitution-inflammatory-
syndrome appeared, steroid treatment was initiated. Steroid treatment was then continued
until no virus could be detected in the cerebrospinal fluid.The outcome was favorable. We
believe that this case clearly illustrates the importance of an early, presymptomatic, detec-
tion of PML, and an adequate treatment.We also propose that surveillance with MRI scans,
every 3 months after 24 months of treatment, should be performed in JC virus antibody
positive natalizumab-treated MS patients in order to detect PML in an early phase.
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CASE PRESENTATION
In February 2008, a 39-year-old man was diagnosed with ulcera-
tive colitis and treatment was initiated with azathioprine. He also
suffered from Graves’ disease (causing strabismus and diplopia)
and underwent a thyroidectomy. Azathioprine was discontinued
in August 2008 due to abnormal liver function. At that time, he
began to experience numbness and weakness of both legs and
his left arm. Magnetic resonance imaging [MRI; Signa Twinspeed
1.5 T (General Electric)] showed multiple lesions typical for mul-
tiple sclerosis (MS) of both the brain (9 lesions) and spinal cord
(20 lesions; Figure 1). No gadolinium enhancement was seen.
The patient’s tendon reflexes were clearly exaggerated in both legs
and he experienced a decreased sensation of vibration. Babinski’s
sign was present. He also experienced urinary retention and the
need for intermittent catheterization. Analysis of the cerebrospinal
fluid (CSF) showed oligoclonal IgG bands. The patient’s score on
Kurtzke Expanded Disability Status Scale (EDSS) was 5.5 (on a
scale ranging from 0 to 10, with higher scores indicating a greater
degree of disability). Thus, within a year, he had been diagnosed
with three different autoimmune diseases.
NATALIZUMAB THERAPY
Due to a presumed highly active MS disease, intravenous
natalizumab therapy (at a dose of 300 mg every 4 weeks) was
initiated already in December 2008. This treatment was also
considered effective for his colitis. Despite natalizumab treat-
ment, he developed severe spasticity and pain in his legs, therefore
baclofen and duloxetine treatment was initiated in May 2009. At
that time, he could still walk short distances with the aid of a cane
and EDSS was 6.0. MRI in March 2010 showed no new lesions,
and there were no clinical relapses. However, in May 2011, MRI
showed a new lesion in the cervical spinal cord and he experienced
accentuated spasticity in his legs and left arm. EDSS was now 7.5
and he was confined to a powered wheelchair, but his cognitive
functions still seemed intact. He was home living but he needed
human help to complete activities of daily living (ADL). In August
2011, he tested positive for JC virus antibodies. In order to treat
his severe spasticity, he was treated with nabiximols (Sativex) from
February to April 2012. In late April 2012, after 44 natalizumab
infusions, a routine MRI scan showed a diffusely demarcated pari-
etal subcortical lesion in the right hemisphere (Figures 2 and 3).
At that time, the patient’s EDSS was still 7.5, and he had not expe-
rienced any new neurological symptoms. However, he scored only
42 on a Symbol Digit Modalities Test (SDMT; see Discussion).
In a test 6 months earlier he had scored 51, and in December
2008, when natalizumab treatment was initiated, he had scored
46. PML was suspected and later confirmed when analysis of
the CSF with a polymerase-chain-reaction (PCR) assay for JC
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FIGURE 1 | Initial MRI 2D Flair of the brain (A–C) and FSTIR of the spinal cord (D,E) at the time of MS diagnosis. Arrows indicate MS lesions.
virus DNA showed 7100 copies/milliliter. The CSF showed no
pleocytosis.
TREATMENT OF PML
Plasma exchange was immediately initiated to accelerate removal
of natalizumab, in order to restore immune function, with a total
of five treatments every second day. Moreover, mefloquine 250 mg
was added once daily for three consecutive days followed by once
a week, and mirtazapine 30 mg was added once daily. Directly
after the plasma exchange, MRI displayed a new PML lesion adja-
cent to the splenium in the left hemisphere, and the initial lesion
in the right hemisphere had increased in size (Figure 2). MRI
was performed twice a week to immediately discover any signs of
gadolinium enhancement, indicating an immune-reconstitution-
inflammatory-syndrome (IRIS) reaction. In mid June, approx-
imately 1 month after the plasma exchange, his legs suddenly
became weaker and he complained of headache. IRIS was now
suspected and intravenous solumedrole treatment, 1 g daily for
five consecutive days, was initiated. However, MRI 2 days later still
showed no gadolinium enhancement, perhaps due to the steroid
treatment which had already been initiated. At this time, in the
left hemisphere, the lesion adjacent to the splenium had further
increased in size (Figure 2). In the right hemisphere, the initial
lesion had also increased in size, and additional lesions appeared
in the superior frontal lobe and splenium (Figures 2 and 3). At
no time during the whole course of the disease was any con-
trast enhancement detected on MRI. Directly after solumedrole,
prednisolone at a dose of 30 mg, once daily, was initiated. A new
CSF analysis of JC virus DNA in July, 2.5 months after plasma
exchange, showed 510 copies/ml and pleocytosis (10 mono). A last
CSF analysis in August, 3.5 months after the last plasma exchange,
was negative for JC virus DNA, and no pleocytosis was at hand.
Prednisolone dose was then tapered off over a period of 4 weeks.
He is from October 2012 treated with interferon beta-1a (Reb-
if® 44µg). In November 2012, 7 months after PML diagnosis, he
scored 35 on SDMT. EDSS was not changed (7.5), and he could
still drive his powered wheelchair independently. He is still home
living and needs human help for his ADL. However, he complains
of increased spasticity in his legs and left arm. He also experienced
fatigue. An MRI scan performed in November 2012 displayed lam-
inar necrosis in the initial PML lesion in the right parietal lobe
(Figure 4).
Frontiers in Neurology | Multiple Sclerosis and Neuroimmunology February 2013 | Volume 4 | Article 11 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lindå and von Heijne Diagnosis and treatment of natalizumab-associated PML
FIGURE 2 | Magnetic resonance imaging scans during the course of PML
and IRIS. Axial reconstructions from 3D Flair acquisition. Routine MRI 1 year
before PML diagnosis (A), when PML was diagnosed (B) and subsequent
scans directly after plasma exchange (C), 1 week (D), 2 weeks (E), 4 weeks
(F), 5 weeks (G), 1.5 months (H), and 2.5 months (I) after plasma exchange.
Arrows indicate the PML lesions.
BACKGROUND
Natalizumab (Tysabri®) was introduced for the treatment of
highly active relapsing-remitting MS in November 2004. Natal-
izumab is a monoclonal antibody directed against α4β1 and α4β7
integrins that prevents inflammatory cells from binding to brain
endothelial cells and passing into the brain parenchyma (Stüve
et al., 2006). Natalizumab is highly effective with a clear reduc-
tion in relapse rate, a reduction in new T2-weighted and T1
contrast enhancing lesions (Rudick et al., 2006; Polman et al.,
2006). As of December 2012, more than 100,000 patients have
been treated with natalizumab worldwide, and among them more
than 20,000 with a treatment duration exceeding 4 years (Biogen
Idec, data on file). Progressive multifocal leukoencephalopathy
(PML) is a rare and often fatal demyelinating disease of the
central nervous system (CNS) that occurs in immunocompro-
mised patients as in, for example, myelo- and lymphoproliferative
disorders or human immunodeficiency virus (HIV)/AIDS (Koral-
nik, 2004). The etiological agent is the human JC polyomavirus
(JCV) which remains latent in the kidneys and lymphoid organs
of infected immunocompetent patients. In infected immunocom-
promised patients the JCV could mutate and infect oligodendro-
cytes which causes multifocal demyelination. Another cause of
PML is immunosuppressive drug therapy such as natalizumab
(Kleinschmidt-DeMasters and Tyler, 2005; Langer-Gould et al.,
2005; Yousry et al., 2006; Lindå et al., 2009). As of December 2012,
312 cases of natalizumab-associated PML have been reported (Bio-
gen Idec, data on file). Natalizumab-associated PML infections
are lethal in approximately 20% of cases, and among survivors it
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FIGURE 3 | Magnetic resonance imaging scans during the course of PML
and IRIS. Sagittal reconstructions through the right hemisphere from 3D Flair
acquisition. Routine MRI 1 year before PML was diagnosed (A), when PML
was diagnosed (B) and subsequent scans 2 weeks (C), 1.5 months (D),
2.5 months (E), and 3.5 months (F) after plasma exchange. Arrows indicate
the PML lesions.
most often leads to severe disability (Vermersch et al., 2011). Three
main risk factors for natalizumab-PML are known, i.e., 1/prior
JC virus infection with the presence of anti-JC virus antibodies,
2/prior use of immunosuppressants, and 3/a treatment duration
exceeding 24 months (Bloomgren et al., 2012). In the general pop-
ulation with MS, approximately 55% are JC virus antibody positive
(Bloomgren et al., 2012). No PML cases have been confirmed
in JC virus antibody negative patients. With a positive anti-JC
virus antibody status, the incidence of PML is 0.56 (0.36–0.83)
per 1000 patients when there are no prior use of immunosup-
pressants and a treatment duration shorter than 24 months. In
contrast, the incidence is 11.1 (8.3–14.5) per 1000 in JC virus anti-
body positive patients with a prior use of immunosuppressant
and a treatment duration exceeding 24 months (Bloomgren et al.,
2012).
DISCUSSION
We describe a patient with natalizumab treatment who, based on
findings on a routine MRI scan, was diagnosed with PML before
any unambiguous clinical manifestations had emerged. PML is
a serious adverse effect with high morbidity and mortality rates
complicating natalizumab treatment. Clinical vigilance is always
important for the diagnosis, but this case clearly illustrates the
importance of an early detection with MRI and an adequate treat-
ment to accomplish a favorable outcome. A few short case reports
have recently been published of PML discovered by MRI in the
presymptomatic phase (Blair et al., 2012; Phan-Ba et al., 2012a).
In these cases, clinical outcome was also favorable, but in our case
poor prognosis would be predicted according to factors reported
as associated with poorer survival, i.e., 1/older age at PML diag-
nosis, 2/higher pre-PML EDSS, and 3/widespread PML extension
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FIGURE 4 | Final, stable status, 7months after PML diagnosis. 3D Flair (A–G) and T1w SE (H,I). (H,I) Show laminar necrosis in part of the initial lesion.
Arrows in (A–G) indicate the PML lesions and in (H,I) the laminar necrosis.
on MRI (Biogen Idec, data on file). This is in line with emerg-
ing evidence that early diagnosis of PML, before any symptoms
develop, is of importance for the outcome (Phan-Ba et al., 2012b).
Thus, we are convinced that MRI scans (FLAIR) every 3 months
after 24 months of natalizumab treatment, when risk to develop
PML is increased, should be recommended in all JC virus positive
MS patients (Table 1). It is probably even more important with
frequent MRI scans among natalizumab treated MS patients with
a high EDSS score, as shown in this case, while it is more diffi-
cult to discover a subtle clinical worsening among these patients.
Our patient also had a prior use of immunosuppressant, which
further emphasize the importance of frequent MRI scans in such
cases. The importance of frequent MRI scans was also obvious
in our first case of natalizumab-associated PML, which also was
the first case described with natalizumab monotherapy (Lindå
et al., 2009). In that case, we could demonstrate that signs of
PML on MRI was at hand already 3 months before any symp-
toms had appeared (Lindå et al., 2009). In the present case, regular
MRI scans every 3 months, most probably would have discovered
the PML infection even earlier, which possibly would have led to
an even more favorable outcome. The present case also demon-
strates the importance of frequent SDMT, while the patient’s score
was clearly lower at PML diagnosis compared to 6 months earlier.
SDMT measures cognitive processing speed and visual working
memory. It is a performance measure that requires patients to
visually scan a key of number/symbol pairings and then voice
the correct number for randomly presented symbols as rapidly
as possible (Smith, 1982). The outcome measure is the number
of correct responses in 90 s. SDMT is strongly associated with
MS lesion burden and cortical and deep gray matter atrophy
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Table 1 | Proposed scanning surveillance with a complete MRI
protocol yearly and MRI scans with only 3D FLAIR images with
3months interval.
MRI Yearly Month 3 Month 6 Month 9
Protocol SAG 3D FLAIR SAG 3D FLAIR SAG 3D FLAIR SAG 3D FLAIR
Ax T2 FSE
Ax DWI
Ax T1 SE
Ax T1 SE w CM
FLAIR, fluid attenuated inversion recovery; FSE, fast spin echo; DWI, diffusion
weighted imaging; CM, contrast media (gadolinium).
(Houtchens et al., 2007; Benedict et al., 2006). However, there is
often some variation in scores between tests in the same patient
over time, which makes it difficult from one test to determine
whether it is a temporary decline in score or a first indication of
PML. A monthly assessment should then be necessary to screen
for cognitive impairments, instead of the usually scheduled every
6 months. The sensitivity and specificity of SDMT with regard to
early discovery of PML remains to be evaluated. The efficacy of
plasma exchange in the treatment of natalizumab-associated PML
has already been shown in several case reports (Lindå et al., 2009;
Khatri et al., 2009; Schroder et al., 2010; Wenning et al., 2009).
Also in the present case, plasma exchange was initiated immedi-
ately after diagnosis of PML to quickly remove natalizumab, and
thus restore immune function. Mefloquine was given directly after
plasma exchange. Mefloquine has been shown to inhibit JC viral
replication in cells in vitro (Brickelmaier et al., 2009), and to exert
beneficial clinical effects on PML infections (Beppu et al., 2012).
Treatment with mirtazapine (at a dose of 30 mg per day) was
also initiated after plasma exchange to probably further inhibit
viral spread by blocking the 5-HT2 receptor, the proposed viral
coreceptor for cellular infection (Aksamit, 2008). Close clinical
vigilance and frequent MRI scans was then performed in order to
detect the first symptoms suggestive of IRIS. IRIS is a well known
condition from patients with HIV infections suffering from PML,
where it occurs in parallel with immune recovery after highly active
antiretroviral therapy (Venkataramana et al., 2006). It is caused
by the presumed immune attack against the JC virus, resulting
in an overwhelming inflammatory response. This inflammatory
attack is then believed to increase the local damage. Thus, IRIS
itself can probably cause significant morbidity and mortality and
should be treated with steroids (Tan et al., 2009). However, the use
of steroids for IRIS has been challenged (Berger, 2009). IRIS can
be detected either by gadolinium enhancement on MRI or by a
worsening of symptoms. In both this case and in our first case of
natalizumab-associated PML (Lindå et al., 2009), IRIS occurred
within 1 month from plasma exchange and was accompanied by
headache, possibly a consequence of meningeal irritation. In order
not to interfere with the initial immune recovery, we waited with
steroids until a presumed IRIS was at hand. The treatment with
high dose steroids intravenously was followed by an oral steroid
course for several months until PCR for JC virus DNA in CSF
showed negative results.
CONCLUDING REMARKS
Our patient’s history clearly illustrates the importance of fre-
quent MRI scans to detect PML in an early phase, thus antic-
ipating a more favorable outcome. We propose that MRI scans
should be performed every 3 months after 24 months of natal-
izumab treatment among JC virus antibody positive MS patients.
We also propose that natalizumab-associated PML should be
treated according to what is described in this case, i.e., plasma
exchange followed by mirtazapine and mefloquine. Steroid treat-
ment should be initiated when IRIS emerges and continued until
no JC virus DNA can be detected in the CSF. Thus, we herein
provide a possible algorithm for the diagnosis and treatment of
natalizumab-associated PML.
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